Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice.

We examined the effects of a 2,2'-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.

Citation

Eonmi Kim, Sae-Kwang Ku, Sumin Yang, Bong-Seon Lee, Geum Jin Kim, Hyukjae Choi, Jong-Sup Bae. Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice. Journal of Asian natural products research. 2021 Jan;23(1):55-72

Mesh Tags

Substances

PMID: 31888389

search → result